{
    "clinical_study": {
        "@rank": "114523", 
        "brief_summary": {
            "textblock": "To determine the safety, tolerance, and potential in vivo antiviral effects of five dosage\n      levels and a dose to be determined of human anti-cytomegalovirus (CMV) monoclonal antibody\n      (SDZ MSL-109; formerly SDZ 89-109) when administered once every 2 weeks for a total of 12\n      doses to patients with either AIDS or eligible AIDS-related complex (ARC) and with culture\n      proven evidence of CMV viremia and/or viruria. Sandoglobulin will be employed as a\n      comparative control."
        }, 
        "brief_title": "A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria", 
        "condition": [
            "Cytomegalovirus Infections", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Cytomegalovirus Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n          -  Acyclovir.\n\n          -  Experimental maintenance or prophylactic therapy with an approved therapeutic agent\n             for a non-viral opportunistic infection.\n\n          -  Trimethoprim / sulfamethoxazole (TMP / SMX).\n\n          -  Pyrimethamine / sulfadoxine.\n\n          -  Inhaled pentamidine.\n\n          -  Amphotericin B.\n\n          -  Ketoconazole.\n\n          -  Flucytosine (5-FC).\n\n          -  Antituberculosis therapy.\n\n          -  Recombinant human erythropoietin.\n\n          -  Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF).\n\n          -  Recombinant human interferon alfa 2 for AIDS-related Kaposi's sarcoma.\n\n        Patients must have:\n\n          -  AIDS or be HIV positive with CD4 lymphocyte counts below 200 cells/mm3 and be\n             receiving prophylaxis for Pneumocystis carinii pneumonia (PCP) (with or without\n             prophylaxis for another opportunistic infection), but have no prior medical history\n             of an opportunistic infection.\n\n          -  Expected survival of = or > 6 months.\n\n          -  Willingness and ability to give written informed consent.\n\n          -  A copy of the signed and witnessed consent form must be maintained with the\n             investigator's study files.\n\n          -  Positive culture results documenting the presence of cytomegalovirus (CMV) viremia\n             and/or viruria.\n\n          -  Seropositive for the presence of circulating anti-CMV immunoglobulin.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Significant pulmonary dysfunction.\n\n          -  Uncontrolled or unstable diabetes.\n\n          -  Significant cardiovascular disease including uncontrolled hypertension, congestive\n             heart failure, cardiac arrhythmia, angina pectoris, or a history of myocardial\n             infarction within one year of entry into the study.\n\n          -  Coagulation or hemorrhagic disorders.\n\n          -  Any active severe opportunistic infection.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Therapy with ganciclovir (DHPG) or phosphonoformate (PFA) or other experimental\n             anti-cytomegalovirus therapy except as stipulated in this protocol.\n\n          -  Any other experimental antiviral therapy.\n\n          -  Biologicals including immunoglobulin therapy (except those patients randomized to\n             receive Sandoglobulin as specified in this protocol).\n\n        Patients with the following are excluded:\n\n          -  Any significant organ system dysfunction as described in Exclusion co-existing\n             conditions.\n\n          -  Previous history of or evidence of idiopathic thrombocytopenia purpura,\n             agammaglobulinemia, or hypogammaglobulinemia.\n\n          -  Any other severe concomitant clinical condition.\n\n          -  Documented, active cytomegalovirus (CMV) disease (tissue or organ\n             invasion/dysfunction) at baseline.  To this end, baseline indirect funduscopy (to\n             detect and exclude patients with peripheral CMV retinitis) will be performed.\n\n        Prior Medication:\n\n        Excluded within 2 weeks of study entry:\n\n          -  Therapy with ganciclovir (DHPG) or phosphonoformate (PFA) or other experimental\n             anti-cytomegalovirus therapy except as stipulated in this protocol.\n\n          -  Any other experimental antiviral therapy.\n\n          -  Biologicals including immunoglobulin therapy (except those patients randomized to\n             receive Sandoglobulin as specified in this protocol).\n\n          -  Excluded:\n\n          -  Prior treatment with monoclonal antibodies derived from any animal species.\n\n        Prior Treatment:\n\n        Excluded within 2 weeks of study entry:\n\n          -  Major surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002268", 
            "org_study_id": "071A", 
            "secondary_id": "Study No B102"
        }, 
        "intervention": {
            "intervention_name": "Sevirumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Antiviral Agents"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Immunotherapy", 
            "Drug Evaluation", 
            "Cytomegalovirus Infections", 
            "Antibodies, Monoclonal"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Univ of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77550"
                    }, 
                    "name": "Univ TX Galveston Med Branch"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002268"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1991"
    }, 
    "geocoordinates": {
        "Univ TX Galveston Med Branch": "29.301 -94.798", 
        "Univ of Alabama at Birmingham": "33.521 -86.802"
    }
}